PD-1/PD-L1 Based Combinational Cancer Therapy: Icing on the Cake

Nab‐paclitaxel in older patients with non–small cell lung cancer who have developed disease progression after platinum‐based doublet chemotherapy

(2020) Jared M. Weiss et al.   CANCER

Cytokines as potential combination agents with PD‐1/PD‐L1 blockade for cancer treatment

(2020) Ghasem Rahimi Kalateh Shah Mohammad et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Engineering of Upconverted Metal–Organic Frameworks for Near-Infrared Light-Triggered Combinational Photodynamic/Chemo-/Immunotherapy against Hypoxic Tumors

(2020) Yulei Shao et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Cost‐effectiveness analysis of pembrolizumab plus chemotherapy with PD‐L1 test for the first‐line treatment of NSCLC

(2020) Ning Wan et al.   Cancer Medicine

IL1α Antagonizes IL1β and Promotes Adaptive Immune Rejection of Malignant Tumors

(2020) Tian Tian et al.   Cancer Immunology Research

A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer

(2020) Qianqian Ni et al.   Science Advances

Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study

(2019) Anas Younes et al.   Lancet Haematology

Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

(2019) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

(2019) Brian I. Rini et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study

(2019) Yung-Jue Bang et al.   Gastric Cancer

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

(2019) Howard West et al.   LANCET ONCOLOGY

Restriction of PD-1 function by cis-PD-L1/CD80 interactions is required for optimal T cell responses

(2019) Daisuke Sugiura et al.   SCIENCE

Ivermectin reverses the drug resistance in cancer cells through EGFR/ERK/Akt/NF-κB pathway

(2019) Lu Jiang et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Characterization of a novel anti-human lymphocyte activation gene 3 (LAG-3) antibody for cancer immunotherapy

(2019) Xiaojie Yu et al.   mAbs

A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women’s cancers with biomarker analyses

(2019) Alexandra S. Zimmer et al.   Journal for ImmunoTherapy of Cancer

Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G4 Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial

(2019) Xinan Sheng et al.   JOURNAL OF CLINICAL ONCOLOGY

Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial

(2019) Michael Friedlander et al.   LANCET ONCOLOGY

Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human PD-1xLAG-3 Knock-In Mice

(2019) Elena Burova et al.   MOLECULAR CANCER THERAPEUTICS

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2019) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B‐cell lymphoma

(2019) Alex F. Herrera et al.   AMERICAN JOURNAL OF HEMATOLOGY

ENERGIZE: a Phase III study of neoadjuvant chemotherapy alone or with nivolumab with/without linrodostat mesylate for muscle-invasive bladder cancer

(2019) Guru Sonpavde et al.   Future Oncology

PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways

(2019) Yunlong Zhao et al.   IMMUNITY

First report of overall survival for ipilimumab plus nivolumab from the phase III Checkmate 067 study in advanced melanoma

(2018) S Turajlic et al.   ANNALS OF ONCOLOGY

Cancer statistics, 2018

(2018) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer

(2018) Matthew D. Hellmann et al.   CANCER CELL

Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors

(2018) Jason J. Luke et al.   JOURNAL OF CLINICAL ONCOLOGY

Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer

(2018) Michael J. Overman et al.   JOURNAL OF CLINICAL ONCOLOGY

Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy

(2018) Kui Li et al.   JOURNAL OF DRUG TARGETING

Nivolumab plus ipilimumab in metastatic colorectal cancer

(2018) Elizabeth Gourd   LANCET ONCOLOGY

ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial

(2018) John M Wrangle et al.   LANCET ONCOLOGY

Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials

(2018) Sandra P D'Angelo et al.   LANCET ONCOLOGY

Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study

(2018) Georgina V Long et al.   LANCET ONCOLOGY

Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial

(2018) Michael B Atkins et al.   LANCET ONCOLOGY

Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial

(2018) Toni K Choueiri et al.   LANCET ONCOLOGY

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

(2018) Leena Gandhi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

(2018) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Complete Local and Abscopal Responses from a Combination of Radiation and Nivolumab in Refractory Hodgkin's Lymphoma

(2018) Qian Qin et al.   RADIATION RESEARCH

A pilot study of durvalumab and tremelimumab and immunogenomic dynamics in metastatic breast cancer

(2018) Cesar August Santa-Maria et al.   Oncotarget

EGFR–TKI-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients With Non–Small Cell Lung Cancer

(2018) Yasuo Oshima et al.   JAMA Oncology

Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non–small-cell lung cancer

(2018) Stephen V. Liu et al.   EUROPEAN JOURNAL OF CANCER

24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non–Small Cell Lung Cancer

(2018) Hossein Borghaei et al.   Journal of Thoracic Oncology

Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials

(2018) Wenfeng Fang et al.   LANCET ONCOLOGY

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

(2018) Leora Horn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

(2018) Luis Paz-Ares et al.   NEW ENGLAND JOURNAL OF MEDICINE

SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study

(2018) Antoni Ribas et al.   Cancer Discovery

Cost-effectiveness of pembrolizumab in combination with chemotherapy in the 1st line treatment of non-squamous NSCLC in the US

(2018) Ralph P. Insinga et al.   JOURNAL OF MEDICAL ECONOMICS

A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization

(2018) Miguel F. Sanmamed et al.   CELL

JAVELIN Head and Neck 100: a Phase III trial of avelumab and chemoradiation for locally advanced head and neck cancer

(2018) Yao Yu et al.   Future Oncology

Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial

(2018) Frank Stephen Hodi et al.   LANCET ONCOLOGY

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

(2018) Peter Schmid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations

(2018) Fatima Karzai et al.   Journal for ImmunoTherapy of Cancer

More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments

(2017) L. Kandolf Sekulovic et al.   EUROPEAN JOURNAL OF CANCER

Radiosurgery/stereotactic radiotherapy in combination with immunotherapy and targeted agents for melanoma brain metastases

(2017) Elisabetta Trino et al.   Expert Review of Anticancer Therapy

Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study

(2017) Jung-Min Lee et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study

(2017) Hans J. Hammers et al.   JOURNAL OF CLINICAL ONCOLOGY

Development of a robust reporter gene assay to measure the bioactivity of anti-PD-1/anti-PD-L1 therapeutic antibodies

(2017) Lan Wang et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial

(2017) Georgina V Long et al.   LANCET ONCOLOGY

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2017) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cost-effectiveness of nivolumab for recurrent or metastatic head and neck cancer☆

(2017) Matthew C. Ward et al.   ORAL ONCOLOGY

Checkpoint inhibition in pediatric hematologic malignancies

(2017) Kara L. Davis et al.   PEDIATRIC HEMATOLOGY AND ONCOLOGY

Parthenolide suppresses non-small cell lung cancer GLC-82 cells growth via B-Raf/MAPK/Erk pathway

(2017) Minting Lin et al.   Oncotarget

Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy

(2017) Hyunju Lee et al.   Cancer Immunology Research

Euphorbia factor L2 induces apoptosis in A549 cells through the mitochondrial pathway

(2017) Minting Lin et al.   Acta Pharmaceutica Sinica B

Advancing Cancer Therapy with Present and Emerging Immuno-Oncology Approaches

(2017) Jeff Kamta et al.   Frontiers in Oncology

Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies

(2016) J. Naidoo et al.   ANNALS OF ONCOLOGY

Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study

(2016) S. Kanda et al.   ANNALS OF ONCOLOGY

Atezolizumab: First Global Approval

(2016) Anthony Markham   DRUGS

57O Efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib (G): A phase I expansion in TKI-naïve patients (pts) with EGFR mutant NSCLC

(2016) D.L. Gibbons et al.   Journal of Thoracic Oncology

Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study

(2016) Scott Antonia et al.   LANCET ONCOLOGY

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial

(2016) F Stephen Hodi et al.   LANCET ONCOLOGY

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

(2016) Corey J Langer et al.   LANCET ONCOLOGY

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology

(2016) Mark J. Selby et al.   PLoS One

Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma

(2016) Jeffrey J. Wallin et al.   Nature Communications

Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy

(2016) Ju Yeon Lee et al.   Nature Communications

Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy

(2016) Maarten Swart et al.   Frontiers in Oncology

The modulation of ABC transporter-mediated multidrug resistance in cancer: A review of the past decade

(2015) Rishil J. Kathawala et al.   DRUG RESISTANCE UPDATES

Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

(2015) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti–PD-1 Therapy in Melanoma

(2015) Blanca Homet Moreno et al.   SEMINARS IN ONCOLOGY

Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system

(2015) Yago Pico de Coaña et al.   TRENDS IN MOLECULAR MEDICINE

Mechanisms of resistance to EGFR tyrosine kinase inhibitors

(2015) Lihua Huang et al.   Acta Pharmaceutica Sinica B

Blockade of the B7-H1/PD-1 Pathway as a Basis for Combination Anticancer Therapy

(2014) Mario Sznol   CANCER JOURNAL

Effects of Human Anti-Spike Protein Receptor Binding Domain Antibodies on Severe Acute Respiratory Syndrome Coronavirus Neutralization Escape and Fitness

(2014) J. Sui et al.   JOURNAL OF VIROLOGY

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer

(2013) S A Quezada et al.   BRITISH JOURNAL OF CANCER

Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer

(2013) M. Sznol et al.   CLINICAL CANCER RESEARCH

Epigenetic regulation of angiotensin-converting enzyme 2 (ACE2) by SIRT1 under conditions of cell energy stress

(2013) Nicola E. Clarke et al.   CLINICAL SCIENCE

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sildenafil Reverses ABCB1- and ABCG2-Mediated Chemotherapeutic Drug Resistance

(2011) Z. Shi et al.   CANCER RESEARCH

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Transcriptional analysis of HIV-specific CD8+ T cells shows that PD-1 inhibits T cell function by upregulating BATF

(2010) Michael Quigley et al.   NATURE MEDICINE